Kathleen Moore, MD

Articles

Dr. Moore on Anticipated Impact of the MIRASOL Trial in Platinum-Resistant Ovarian Cancer

September 2nd 2020

Kathleen Moore, MD, discusses the anticipated impact of the phase 3 MIRASOL trial with mirvetuximab soravtansine in patients with platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with a high folate receptor alpha expression.

Dr. Moore on the Prevalence of Ovarian Cancer

July 29th 2020

Kathleen Moore, MD, discusses the current prevalence of ovarian cancer.

Dr. Moore on Unmet Clinical Needs in Platinum-Resistant Ovarian Cancer

July 17th 2020

Kathleen Moore, MD, discusses the unmet clinical needs in platinum-resistant ovarian cancer.

Dr. Moore on Early-Phase Data With Mirvetuximab Soravtansine in Ovarian Cancer

April 3rd 2020

Kathleen Moore, MD, discusses the early phase data that led to the development of the phase III FORWARD I/ GOG 3011 trial in ovarian cancer.

Dr. Moore on Safety Profile of Mirvetuximab Soravtansine in Ovarian Cancer

March 27th 2020

Kathleen Moore, MD, discusses the safety profile of mirvetuximab soravtansine, an antibody-drug conjugate that targets the FRα transmembrane protein, in ovarian cancer.

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian Cancer

March 4th 2020

Kathleen Moore, MD, director, Oklahoma TSET Phase I Clinical Trials Program, and associate professor, Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director, Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, discusses the role of mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Dr. Moore on Results of the FORWARD I/GOG 3011 Trial in Ovarian Cancer

February 14th 2020

Kathleen Moore, MD, discusses topline findings from the phase III FORWARD I/GOG 3011 trial in ovarian cancer.

Dr. Moore on Benefit of Mirvetuximab Soravtansine in Ovarian Cancer

January 21st 2020

Kathleen Moore, MD, discusses the benefit of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer.

Dr. Moore on Treatment for Patients With Ovarian Cancer Who Develop Resistance to PARP Inhibitors

January 3rd 2020

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses treatment for patients with ovarian cancer who progress on a PARP inhibitor.

Dr. Moore on Research Evaluating Repeat Exposure to PARP Inhibition in Ovarian Cancer

September 19th 2019

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses research evaluating repeat exposure to PARP inhibition in patients with platinum-sensitive ovarian cancer.

Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

August 22nd 2019

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, poses unanswered questions pertaining to the use and reuse of PARP inhibitors in ovarian cancer treatment.

Dr. Moore on the Results of the NOVA Trial in Ovarian Cancer

May 23rd 2017

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the results of the NOVA trial in ovarian cancer.

Dr. Moore on the NOVA Trial for Ovarian Cancer

March 16th 2017

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.